Methadone Treatment in Primary Care: Experience from Ontario, Canada 1980-2021
Webinar – Wednesday, May 31st @ 7pm ET Lori Regenstreif, MD Andrew McLeod Meldon Kahan, MD As the United States…
Articles
New OASAS Medical Advisory Panel (MAP) Xylazine Guidance
OASAS has posted the new OASAS Medical Advisory Panel (MAP) Xylazine Guidance document. Please share widely with your staff. Please…
Pilot Funding Opportunity: One Year Up to $75,000 for Research
One year of pilot funding of up to $75,000 for research into chronic pain and opioid use disorder IMPOWR-ME is…
Learning Session May 1st – Evidence for the Use of PrEP
Please join us for our upcoming General Membership Learning Session, scheduled for Monday, May 1st from 8-9PM. Pamela Mund, MD,…
NYSPA Addictions Division In-Person Conference
Join The Division on Addictions of the New York State Psychological Association (NYSPA) and the Concentration in Mental Health and…
FDA Approves Over-the-Counter Naloxone
On March 29th, the the U.S. Food and Drug Administration (FDA) approved the first nonprescription, “over-the-counter” (OTC) naloxone nasal spray, Narcan. This…